View in EDS PDF Full Text

The potential of using circulating tumour cells and their gene expression to predict docetaxel response in metastatic prostate cancer.

Saved in:
Bibliographic Details
Title: The potential of using circulating tumour cells and their gene expression to predict docetaxel response in metastatic prostate cancer.
Authors: Davies CR; Centre for Cancer Biomarkers and Biotherapeutics, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom., Guo T; Centre for Cancer Biomarkers and Biotherapeutics, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.; Department of Cell Biology and the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China., Burke E; Centre for Cancer Biomarkers and Biotherapeutics, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom., Stankiewicz E; Centre for Cancer Biomarkers and Biotherapeutics, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.; Central Biobank, Medical University of Gdansk, Gdansk, Poland., Xu L; Centre for Cancer Biomarkers and Biotherapeutics, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.; Department of Urology, Zhongshan Hospital, Fudan University, Shanghai, China., Mao X; Centre for Cancer Biomarkers and Biotherapeutics, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom., Scandura G; Centre for Cancer Biomarkers and Biotherapeutics, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom., Rajan P; Centre for Cancer Cell and Molecular Biology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.; Department of Urology, Barts Health National Health Service Trust (NHS), London, United Kingdom.; Division of Surgery and Interventional Sciences, University College London, London, United Kingdom.; University College London Hospitals, National Health Service (NHS) Foundation Trust, London, United Kingdom., Tipples K; Department of Urology, Barts Health National Health Service Trust (NHS), London, United Kingdom., Alifrangis C; University College London Hospitals, National Health Service (NHS) Foundation Trust, London, United Kingdom.; Department of Medical Oncology, Barts Health National Health Service (NHS) Trust, London, United Kingdom., Wimalasingham AG; Department of Medical Oncology, Barts Health National Health Service (NHS) Trust, London, United Kingdom., Galazi M; Department of Medical Oncology, Barts Health National Health Service (NHS) Trust, London, United Kingdom., Crusz S; Department of Medical Oncology, Barts Health National Health Service (NHS) Trust, London, United Kingdom., Powles T; Department of Urology, Barts Health National Health Service Trust (NHS), London, United Kingdom.; Centre for Experimental Cancer Medicine, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom., Grey A; Department of Urology, Barts Health National Health Service Trust (NHS), London, United Kingdom.; Division of Surgery and Interventional Sciences, University College London, London, United Kingdom.; University College London Hospitals, National Health Service (NHS) Foundation Trust, London, United Kingdom., Oliver T; Centre for Cancer Biomarkers and Biotherapeutics, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom., Kudahetti S; Centre for Cancer Biomarkers and Biotherapeutics, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom., Shaw G; Department of Urology, Barts Health National Health Service Trust (NHS), London, United Kingdom.; Division of Surgery and Interventional Sciences, University College London, London, United Kingdom.; University College London Hospitals, National Health Service (NHS) Foundation Trust, London, United Kingdom., Berney D; Centre for Cancer Biomarkers and Biotherapeutics, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom., Shamash J; Department of Medical Oncology, Barts Health National Health Service (NHS) Trust, London, United Kingdom., Lu YJ; Centre for Cancer Biomarkers and Biotherapeutics, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.
Source: Frontiers in oncology [Front Oncol] 2023 Jan 16; Vol. 12, pp. 1060864. Date of Electronic Publication: 2023 Jan 16 (Print Publication: 2022).
Publication Type: Journal Article
Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
FullText Links:
  – Type: pdflink
Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 36727071
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: The potential of using circulating tumour cells and their gene expression to predict docetaxel response in metastatic prostate cancer.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Davies+CR%22">Davies CR</searchLink>; Centre for Cancer Biomarkers and Biotherapeutics, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Guo+T%22">Guo T</searchLink>; Centre for Cancer Biomarkers and Biotherapeutics, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.; Department of Cell Biology and the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.<br /><searchLink fieldCode="AU" term="%22Burke+E%22">Burke E</searchLink>; Centre for Cancer Biomarkers and Biotherapeutics, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Stankiewicz+E%22">Stankiewicz E</searchLink>; Centre for Cancer Biomarkers and Biotherapeutics, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.; Central Biobank, Medical University of Gdansk, Gdansk, Poland.<br /><searchLink fieldCode="AU" term="%22Xu+L%22">Xu L</searchLink>; Centre for Cancer Biomarkers and Biotherapeutics, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.; Department of Urology, Zhongshan Hospital, Fudan University, Shanghai, China.<br /><searchLink fieldCode="AU" term="%22Mao+X%22">Mao X</searchLink>; Centre for Cancer Biomarkers and Biotherapeutics, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Scandura+G%22">Scandura G</searchLink>; Centre for Cancer Biomarkers and Biotherapeutics, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Rajan+P%22">Rajan P</searchLink>; Centre for Cancer Cell and Molecular Biology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.; Department of Urology, Barts Health National Health Service Trust (NHS), London, United Kingdom.; Division of Surgery and Interventional Sciences, University College London, London, United Kingdom.; University College London Hospitals, National Health Service (NHS) Foundation Trust, London, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Tipples+K%22">Tipples K</searchLink>; Department of Urology, Barts Health National Health Service Trust (NHS), London, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Alifrangis+C%22">Alifrangis C</searchLink>; University College London Hospitals, National Health Service (NHS) Foundation Trust, London, United Kingdom.; Department of Medical Oncology, Barts Health National Health Service (NHS) Trust, London, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Wimalasingham+AG%22">Wimalasingham AG</searchLink>; Department of Medical Oncology, Barts Health National Health Service (NHS) Trust, London, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Galazi+M%22">Galazi M</searchLink>; Department of Medical Oncology, Barts Health National Health Service (NHS) Trust, London, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Crusz+S%22">Crusz S</searchLink>; Department of Medical Oncology, Barts Health National Health Service (NHS) Trust, London, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Powles+T%22">Powles T</searchLink>; Department of Urology, Barts Health National Health Service Trust (NHS), London, United Kingdom.; Centre for Experimental Cancer Medicine, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Grey+A%22">Grey A</searchLink>; Department of Urology, Barts Health National Health Service Trust (NHS), London, United Kingdom.; Division of Surgery and Interventional Sciences, University College London, London, United Kingdom.; University College London Hospitals, National Health Service (NHS) Foundation Trust, London, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Oliver+T%22">Oliver T</searchLink>; Centre for Cancer Biomarkers and Biotherapeutics, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Kudahetti+S%22">Kudahetti S</searchLink>; Centre for Cancer Biomarkers and Biotherapeutics, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Shaw+G%22">Shaw G</searchLink>; Department of Urology, Barts Health National Health Service Trust (NHS), London, United Kingdom.; Division of Surgery and Interventional Sciences, University College London, London, United Kingdom.; University College London Hospitals, National Health Service (NHS) Foundation Trust, London, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Berney+D%22">Berney D</searchLink>; Centre for Cancer Biomarkers and Biotherapeutics, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Shamash+J%22">Shamash J</searchLink>; Department of Medical Oncology, Barts Health National Health Service (NHS) Trust, London, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Lu+YJ%22">Lu YJ</searchLink>; Centre for Cancer Biomarkers and Biotherapeutics, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101568867%22">Frontiers in oncology</searchLink> [Front Oncol] 2023 Jan 16; Vol. 12, pp. 1060864. <i>Date of Electronic Publication: </i>2023 Jan 16 (<i>Print Publication: </i>2022).
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Frontiers+Research+Foundation]%22">Frontiers Research Foundation] </searchLink><i>Country of Publication: </i>Switzerland <i>NLM ID: </i>101568867 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Print <i>ISSN: </i>2234-943X (Print) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%222234943X%22">2234943X </searchLink><i>NLM ISO Abbreviation: </i>Front Oncol <i>Subsets: </i>PubMed not MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=36727071
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.3389/fonc.2022.1060864
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1060864
    Titles:
      – TitleFull: The potential of using circulating tumour cells and their gene expression to predict docetaxel response in metastatic prostate cancer.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Davies CR
      – PersonEntity:
          Name:
            NameFull: Guo T
      – PersonEntity:
          Name:
            NameFull: Burke E
      – PersonEntity:
          Name:
            NameFull: Stankiewicz E
      – PersonEntity:
          Name:
            NameFull: Xu L
      – PersonEntity:
          Name:
            NameFull: Mao X
      – PersonEntity:
          Name:
            NameFull: Scandura G
      – PersonEntity:
          Name:
            NameFull: Rajan P
      – PersonEntity:
          Name:
            NameFull: Tipples K
      – PersonEntity:
          Name:
            NameFull: Alifrangis C
      – PersonEntity:
          Name:
            NameFull: Wimalasingham AG
      – PersonEntity:
          Name:
            NameFull: Galazi M
      – PersonEntity:
          Name:
            NameFull: Crusz S
      – PersonEntity:
          Name:
            NameFull: Powles T
      – PersonEntity:
          Name:
            NameFull: Grey A
      – PersonEntity:
          Name:
            NameFull: Oliver T
      – PersonEntity:
          Name:
            NameFull: Kudahetti S
      – PersonEntity:
          Name:
            NameFull: Shaw G
      – PersonEntity:
          Name:
            NameFull: Berney D
      – PersonEntity:
          Name:
            NameFull: Shamash J
      – PersonEntity:
          Name:
            NameFull: Lu YJ
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 16
              M: 01
              Text: 2023 Jan 16
              Type: published
              Y: 2023
          Identifiers:
            – Type: issn-print
              Value: 2234-943X
          Numbering:
            – Type: volume
              Value: 12
          Titles:
            – TitleFull: Frontiers in oncology
              Type: main
ResultId 1